<div id="readability-page-1"><p>WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) has earned a consensus recommendation of &#34;Moderate Buy&#34; from the fourteen analysts that are  covering the company, MarketBeat Ratings reports. One equities research analyst  has rated the stock with a sell rating and thirteen have given a buy rating to  the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $31.6667.</p><div><p><span></span><span>Get <strong>WAVE Life Sciences</strong> alerts:</span></p></div><ul><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p>Several research firms have weighed in on WVE. UBS Group  set a $32.00 price objective on WAVE Life Sciences in a research report on Tuesday, December 16th. Morgan Stanley  set a $28.00 price target on shares of WAVE Life Sciences in a research note on Monday, December 8th. Wedbush lifted their price objective on shares of WAVE Life Sciences from $20.00 to $33.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, December 12th. Leerink Partners  reissued an &#34;outperform&#34; rating on shares of WAVE Life Sciences in a report on Monday, December 8th. Finally, B. Riley increased their target price on shares of WAVE Life Sciences from $19.00 to $37.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, December 12th.</p><p><b>Read Our Latest Stock Report on WVE</b></p><h2>Insider Transactions at WAVE Life Sciences</h2><ul><li>Wave Life Sciences Rockets 70% on Historic RNA Editing Success</li></ul><p>In other WAVE Life Sciences news, Director Adrian Rawcliffe sold 42,000 shares of the business's stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $15.00, for a total transaction of $630,000.00. Following the completion of the transaction, the director owned 12,700 shares of the company's stock, valued at approximately $190,500. The trade was a 76.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Plc Gsk purchased 1,470,000 shares of WAVE Life Sciences stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $19.00 per share, for a total transaction of $27,930,000.00. Following the completion of the purchase, the insider owned 18,245,691 shares in the company, valued at $346,668,129. This represents a 8.76% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have sold 902,742 shares of company stock valued at $13,313,763. Company insiders own  23.98% of the company's stock. </p><h2>Hedge Funds Weigh In On WAVE Life Sciences</h2><p>A number of institutional investors and hedge funds have recently made changes to their positions in WVE. Adage Capital Partners GP L.L.C. increased its position in  WAVE Life Sciences by 20.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company's stock valued at $97,607,000 after buying an additional 2,500,000 shares in the last quarter.  683 Capital Management LLC grew its stake in  WAVE Life Sciences by 4.5% in the second quarter. 683 Capital Management LLC now owns 4,100,000 shares of the company's stock valued at $26,650,000 after acquiring an additional 175,000 shares during the period.  Federated Hermes Inc. increased its holdings in shares of  WAVE Life Sciences by 678,144.7% during the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company's stock valued at $27,455,000 after acquiring an additional 3,750,140 shares in the last quarter.  Loomis Sayles &amp; Co. L P increased its holdings in shares of  WAVE Life Sciences by 35.3% during the second quarter. Loomis Sayles &amp; Co. L P now owns 3,295,700 shares of the company's stock valued at $21,422,000 after acquiring an additional 859,160 shares in the last quarter.  Finally, Emerald Advisers LLC raised its position in shares of  WAVE Life Sciences by 3.9% during the second quarter. Emerald Advisers LLC now owns 3,257,119 shares of the company's stock worth $21,171,000 after purchasing an additional 123,561 shares during the period. Institutional investors own  89.73% of the company's stock. </p><h2>WAVE Life Sciences Price Performance</h2><ul><li>Sarepta Therapeutics Inc.: Why it's a rising gene therapy star</li></ul><p>Shares of NASDAQ WVE opened at $17.77 on Friday. The stock has a market capitalization of $2.97 billion, a price-to-earnings ratio of -23.69 and a beta of -1.72. The business has a 50-day moving average of $10.52 and a 200-day moving average of $8.77. WAVE Life Sciences has a fifty-two week low of $5.28 and a fifty-two week high of $21.73. </p><p>WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02). WAVE Life Sciences had a negative return on equity of 75.61% and a negative net margin of 111.64%.The company had revenue of $7.61 million for the quarter, compared to the consensus estimate of $9.85 million.  On average, sell-side analysts expect that  WAVE Life Sciences will post -1.14 EPS for the current year. </p><h2>WAVE Life Sciences Company Profile</h2> (Get Free Report)<p>WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.  </p><p>The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than WAVE Life Sciences</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>Trump's $500B plan is fueling these monthly dividends</li><li>[URGENT!] SpaceX Going Public! – Pre-IPO Action</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>Shots officially fired…</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in WAVE Life Sciences Right Now?</h2><p>Before you consider WAVE Life Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list.</p><p>While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>WAVE Life Sciences Ltd. (NASDAQ:WVE) has received a consensus rating of "Moderate Buy" from fourteen analysts, with one rating it as a sell and thirteen as a buy. The average twelve-month price target is $31.67. Recent insider transactions include a major shareholder purchasing 1.47 million shares and a director selling 42,000 shares. Institutional investors own 89.73% of the company's stock. The stock opened at $17.77 on Friday, with a market cap of $2.97 billion.</p>

WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Analysts